Advice
following a full submission
tenofovir disoproxil (as fumarate) (Viread®) is accepted for use within NHS Scotland.
Indication under review: Treatment of chronic hepatitis B in adults with decompensated liver disease.
Interim results of an ongoing phase II study assessing the safety of tenofovir disoproxil in the treatment of chronic hepatitis B in patients with decompensated liver disease demonstrated that tenofovir was as well tolerated as another nucleoside/nucleotide analogue. Comparative efficacy was not tested in this study, but has been extrapolated from a mixed treatment comparison in treatment-naïve patients with compensated liver disease and hepatitis B e-antigen positive infection.
Download detailed advice128KB (PDF)
Medicine details
- Medicine name:
- tenofovir disoproxil (Viread)
- SMC ID:
- 720/11
- Indication:
- Treatment of chronic hepatitis B in adults with decompensated liver disease
- Pharmaceutical company
- Gilead Sciences Ltd
- BNF chapter
- Infections
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 12 September 2011